A Larger Proportion of Hepatitis C Non-Responder Patients Will Be Treated with Telaprevir Than Boceprevir
WALTHAM, Mass., Jan. 19 /PRNewswire/ – Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that U.S. gastroenterologists will treat a larger proportion of treatment nonresponder hepatitis C patients with Vertex/Tibotec/Mitsubishi Tanabe’s telaprevir than Merck’s boceprevir. U.S. gastroenterologists indicate that they would prescribe telaprevir to 50 percent of their hepatitis C non-responder patients. Telaprevir is forecasted to earn 71 percent patient share in the U.S. hepatitis C non-responder market in 2013.
“According to the majority of interviewed clinicians, telaprevir in combination with peg-interferon-alpha-2a/ribavirin will become the treatment of choice for hepatitis C virus genotype 1-infected patients who previously failed the peg-interferon-alpha/ribavirin treatment. Interviewed and surveyed gastroenterologists are also convinced that interferon-alphas will continue to be the backbone of hepatitis C treatment for the non-responder population for the next five to ten years and that ribavirin will also likely continue to be part of the standard of care,” stated Alexandra Makarova, M.D., Ph.D.
The new report entitled Hepatitis C Virus Treatment Non-Responders: Hope on the Horizon with the Imminent Introduction of HCV-Targeted Therapeutics also finds that the combination of telaprevir, Roche’s Pegasys and ribavirin will earn Decision Resources’ proprietary clinical gold standard status in 2013 for hepatitis C treatment non-responders following its approval for the indication in 2011. This regimen has a significant advantage over the current standard of care regimen (pegylated interferon/ribavirin) in terms of efficacy as well as the potential to shorten treatment in some hepatitis C patients who previously failed pegylated interferon/ribavirin treatment.
Members of the media are welcome to attend our upcoming webinar entitled Looking Beyond Triple Therapy for the Hepatitis C Non-Responders Population: U.S. and European Physician Expectations and Perceptions About Quadruple Therapy. This webinar will be held on Thursday, February 18, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at email@example.com.
About the Report
Hepatitis C Virus Treatment Non-Responders: Hope on the Horizon with the Imminent Introduction of HCV-Targeted Therapeutics is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com .
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Gisselle Morales Christopher Comfort 781-296-2691 781-296-2597 firstname.lastname@example.org email@example.com
SOURCE Decision Resources